Progress in the Therapeutic Applications of siRNAs Against HIV-1
Therapeutic options against the human immunodeficiency virus type 1 (HIV-1) continue to expand with the development of new drugs and new therapeutic strategies. Nevertheless, management of HIV-1 infected individuals has become increasingly complex. The emergence of drug-resistant variants, the growing recognition of the long-term toxicity of antiretroviral therapies and the persistence of viral reservoirs justify the continued efforts to develop new anti-HIV-1 strategies. Recent advances regarding the utility of RNA-mediated interference (RNAi) to specifically inhibit HIV-1 replication have opened new possibilities for the development of gene-based therapies against HIV-1 infection. Here, the recent advances in siRNA-based therapies are reviewed.
- Expression of Multisubunit Proteins in Leishmania tarentolae
- Measurement of TNF and iNOS mRNA Using cDNA-Equalized Reverse Transcriptase PCR
- Detection of Allo-HLA Cross-Reactivity by Virus-specific Memory T-Cell Clones Using Single HLA-Transfected K562 Cells
- An RNA Polymerase II In Vitro Transcription System
- Genomic Imprinting in Plants
- Estimating Gene Function With Least Squares Nonnegative Matrix Factorization
- Adenovirus-Mediated Transduction of Auto- and Dual-Regulated Transgene Expression in Mammalian Cells
- Gene Targeting Vector Design for Embryonic Stem Cell Modifications
- Expression Monitoring Using cDNA Microarrays: A General Protocol
- Production of Multicopy shRNA Lentiviral Vectors for Antiviral Therapy